David S. Chu, MD is Founder and Director of Metropolitan Eye Research and Surgery Institute of New York and New Jersey. Dr. Chu is also Clinical Associate Professor of Ophthalmology at the Institute of Ophthalmology and Visual Science, New Jersey Medical School of Rutgers University, in Newark, New Jersey. He serves as the Medical Director of Eversight Eyebanks and as a Board member of Eversight International. He also serves on the Board of Ocular Immunology and Uveitis Foundation. He is the current Immediate Past President of the Foster Ocular Immunology Society. He is also the Co-Founder and Co-President of Sonoma Eye, a scientific congress that attracts attendees with interest in ocular inflammation from around the world. He is also the team ophthalmologist for the New York Jets. Dr. Chu received his medical degree from New York University School of Medicine in 1995. He finished his internship at St. Vincent’s Hospital and Medical Center in New York City. He completed residency in ophthalmology at New York Medical College before completing a fellowship in ocular immunology and uveitis at the Massachusetts Eye and Ear Infirmary of Harvard Medical School. Dr. Chu’s main research interests are focused on understanding, diagnosing and treating ocular inflammatory diseases, including uveitis, scleritis and cicatricial conjunctivitis, such as pemphigoid. He is also interested in the pathophysiology and treatment of corneal infection. He has lectured widely in the United States and abroad on topics in ocular inflammatory diseases and corneal transplantation. Dr. Chu has authored over 100 peer-reviewed journal articles, reviews, book chapters and abstracts.

An internationally recognized physician who specializes in the surgical and medical treatment of retinal disorders. Dr. Diana V. Do is Professor of Ophthalmology and Vice Chair for Clinical Affairs at the Byers Eye Institute, Stanford University School of Medicine. Dr. Do is a board-certified ophthalmologist and is an expert in the management of age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, retinal detachment, macular hole, retinal infections, and epiretinal membrane. She incorporates state-of-the-art treatment options for her patients while treating each individual with compassion and dignity. Her goal is to provide the highest level of care for each patient. Dr. Do is a leading clinician-scientist who has authored over 150 publications in the medical literature and has contributed to over 25 book chapters. She has been the principal investigator and co-investigator on more than 45 clinical trials investigating novel treatments for retinal diseases and ocular inflammation. She has been an invited lecturer throughout the North and South America, Europe, and Asia. Furthermore, she has directed and participated in many continuing medical education courses for ophthalmologists and retina specialists throughout the United States. Before joining Stanford, Dr. Do was Associate Professor of Ophthalmology at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine in Baltimore, Maryland. At Hopkins, she was Head of the Retina Fellowship Training Program. After her tenure at Johns Hopkins, she was recruited to serve as Vice Chair of Education and Professor of Ophthalmology at the University of Nebraska College of Medicine. In addition, she was Program Director of the ophthalmology residency training program and Director of the Retinal Fellowship Training Program at Nebraska. Dr. Do was educated at the University of California at Berkeley where she graduated summa cum laude with a Bachelor of Arts in Molecular and Cellular Biology. She received her medical degree (Alpha Omega Alpha) and was a Regents Scholar at the University of California San Francisco School of Medicine. After completing her medicine internship at Massachusetts General Hospital / Harvard Medical School, she pursued both her ophthalmology training and retina fellowship at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine. Her academic achievements have been recognized with numerous national awards including the Heed Ophthalmic Foundation Clinician-Scientist Award, the Ronald Michels Fellowship Foundation Award, the Honor Award from the American Society of Retina Specialists, and the Achievement Award from the American Academy of Ophthalmology. Dr. Do serves as Vice Chair for Clinical Affairs for the Department of Ophthalmology. In addition, she is the Physician Improvement Leader for Quality Improvement (QI) and collaborates on numerous QI projects with faculty to improve patient experience, quality, and access to outstanding eye care at the Byers Eye Institute. She has an active clinical and surgical practice while she continues to investigate novel treatments for retinal diseases. In addition, Dr. Do teaches students, residents, and retina fellows at Stanford, and she is a member of the Education Committee.

Born in Saigon, Vietnam, and immigrated with his parents and three brothers to the United States in 1980, Dr. Quan Dong Nguyen currently is Professor of Ophthalmology and Director of the Uveitis and Ocular Inflammation Service at the Byers Eye Institute, Stanford University School of Medicine. After completing his education in 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, and Assistant Dean for Translational Research at the University of Nebraska Medical Center. Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous other clinical trials involving novel therapeutic agents. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. Dr. Nguyen and his team were among the first clinician scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME); the initial results of these studies served as the foundation for subsequent trials leading to the approval of these pharmacologic agents by the FDA and other regulatory authorities for the indicated diseases. Dr. Nguyen has chaired the United States multi-center READ-2, READ-3, and iDEAL studies, evaluating the potential role of VEGF antagonists, through different pathways, for diabetic macular edema.Dr. Nguyen has lead the SAVE, and the multi-centered SAVE-2, and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition, in uveitis and ocular inflammatory diseases. Throughout his career thus far, Dr. Nguyen has been prolific to share his scientific work through numerous manuscripts published in the literature. He serves on the Editorial Board of several journals, including the Journal of Ophthalmic Infection and Inflammation and Ophthalmic Surgery, Laser, and Imaging – Retina, among others. Given his scientific achievements and accomplishments, Dr. Nguyen has been chosen as the Inaugural Editor-in-Chief of American Journal of Ophthalmology Case Reports, which has been launched in the fall of 2015 as the companion journal to the American Journal of Ophthalmology. At the Byers Eye Institute at Stanford, Dr. Nguyen has an active uveitis and ocular inflammatory diseases as well as clinical and surgical retina practice while he continues his research in pharmacotherapy and ocular imaging. In addition, he teaches and trains students, residents, and clinical and research retina and uveitis fellows at Stanford.

(MBBS, MD, FAAO ) Dr. Shah is associate professor of ophthalmology specializing in diseases and surgery of heredity and acquired diseases of the retina in the Department of Ophthalmology at the University of Pittsburgh Medical Center. Hailing from a small valley in the Himalayan foothills, Dr. Shah completed his medical education at the Aga Khan University followed by several years of research on ocular neovascularization at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He cofounded the Retinal Imaging Research and Reading Center as well as the Quantum Vison Reading Center. He completed a residency at the Flaum Eye Institute, University of Rochester School of Medicine and a retina fellowship at the Wilmer Eye Institute. Dr. Shah is a recipient of the American Academy of Ophthalmology Achievement Award and is recognized internationally as an expert in heredity retinal diseases and gene therapy.Dr. Shah’s current work includes deep phenotyping heredity retinal degenerations using novel molecular and imaging biomarkers and developing novel targets for neuroprotection. He is an investigator on multiple gene therapy clinical trials. In addition, Dr. Shah is working on integration of data analytics, telemedicine, and artificial intelligence to improve quality, efficiency, and delivery of healthcare in resource-poor populations. To provide low cost and scalable vision screening and rehabilitation services, Dr. Shah is working with an international team to develop augmented reality/virtual reality solutions to enable ocular testing, remote diagnosis, and management.Dr. Shah is a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, and the American Society of Retina Specialists, among others.